Coloplast A/S re-affirmed earnings guidance for the fiscal year 2019. The company continues to expect organic revenue growth of 8% at constant exchange rates and a reported growth in DKK of 9%. The company continues to expect an EBIT margin of 30-31% at constant exchange rates and a reported EBIT margin of 31% in DKK. The company still expect net financials to end the financial year 2018-'2019 at minus DKK 100 million, primarily due to hedging losses on the USD against Danish kroner as a result of the appreciation of the USD against the Danish kroner. The Global Operations Plan 4 is on track and is still expected to deliver an EBIT margin improvement of 100 basis points in '2019-'2020 and 150 basis points in '2020-'2021.